The global Cell and Gene Therapy Bioassay Services market size was accounted at USD 1.63 Bn in 2021; It is projected to grow at a compound annual growth rate (CAGR) of 15.0% from 2022 to 2030. Cell and gene therapy focuses on modifying genetic material to improve functioning or treat a disease. These advanced therapies are one of the highest valued therapeutic segments within the biopharmaceutical industry and can address the most challenging diseases. Bioassay services play a critical role in the cell and gene therapy development process.
The key factors driving the growth of the cell and gene therapy bioassay services market include the high prevalence of chronic diseases and genetic disorders, the rising elderly population, the growing preference of patients toward personalized treatments, and increased technological advancements. Considering the demand for bioassays and the competitiveness of the biologics industry, many drug developers prefer outsourcing bioanalytical services that offer bioassay services for quick and efficient therapy analysis and development. Likely to compel the growth opportunities for the cell and gene therapy bioassay services market in the coming years.
However, the expensive bioassay services offered by the contract research organizations (CROs) may hinder the market growth over the forecast period.
The cell and gene therapy bioassay services market are classified based on the type of therapy, therapeutic area, scale of operation, and region. By type of therapy, the market comprises cell therapy and gene therapy. The cell therapy segment is expected to hold the maximum market share in the coming days owing to the rising demand and awareness regarding cell therapies. The market is classified into oncological, infectious, autoimmune, rare/ genetic, cardiovascular, metabolic, blood, neurological, ophthalmic disorders, and other therapeutic areas in terms of therapeutic area. The oncological segment is expected to be the fastest-growing segment of this market in the coming years, owing to the high prevalence of cancer and the rising aging population. The scale of operation segment is grouped into discovery, preclinical, and clinical. Regionally, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America is projected to dominate this market over the forecast period, followed by Europe and Asia-Pacific.
Some of the key players operating in the cell and gene therapy bioassay services market are AnaBioTec (Belgium), CCRM (Canada), Nexelis (Canada), Pacific BioLabs (US), PPD Laboratories (North Carolina), Intertek Pharmaceutical Services (UK), Lonza (Switzerland), Porton Biopharma Ltd (UK), WuXi Advanced Therapies (US), Avomeen (US), Charles River Laboratories (US), Absorption Systems (US), BioAgilytix Labs (US), Catalent, Inc (US), Svar Life Science AB (Sweden), and others.